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to that of cefotaxime. In two large-scale pediatric meningitis trials in 
Europe, Latin America, the USA. South Africa and Israel, 375 
microbiologically and clinically evaluable children were treated with 
either meropenem (n=191) or cefotaxime (n=184). Both treatment 
groups were found to be similar in clinical and microbiological 
efficacy. There were also comparable incidences of seizures, as well 
as clinical and laboratory adverse events as reported by investigators, 
in the two treatment groups. Based on these data, meropenem can 
be considered an appropriate option for empirical monotherapy 
against Hoemophilus influenzae, type b, Neisseria meniryitidis, and 
currently isolated strains of Strt.procorcus pneumoniae. 
New insights into the pathogenesis and 
therapy of sepsis 
F l  Bacterial CpG DNA activates immune cells to 
signal infectious danger 
H. Wagner. Techn. Urtiuersitiit, Inst. f: Med. Mikrobiologie, Munich, 
Germany 
In contrast to nucleotide triplets used as genetic code to translate 
amino acid sequences, immune cells sensing danger code CpG 
nucleotides in a particular base sequence context, termed CpG 
motifs. The frequency of these CpG motifs is normal in bacterial 
DNA, but suppressed In vertebrate DNA. Macrophages and dendritic 
cells, the sentinels bridging innate and adaptive immunity, take up 
bacterial DNA and become activated by CpG motifs to secrete pro- 
inflammatory cytokines, including IL-1, IL-6 and TNF-alpha, to 
upregulate co-stimulatory molecules, including CD40, CD80 and 
CD86, and to produce effector cytokines such as IL-12 and IL-10. 
As such, bacterial CpG DNA causes CD4GCD40 ligand- 
independent maturation of antigen-presenting cells (APCs). Simlar 
to LPS, bacterial CpG DNA can cause, at the extreme, toxic shock 
due to overproduction of TNF-alpha. When used in therapeutic 
concentrations, bacterial CpG DNA promotes Thl-oriented cell- 
mediated immune responses, as shown for leishmania major, Listeria 
monocytogenes and viral infections. Bacterial CpG motifs act as 
adjuvants for CTL and T h l  responses to soluble proteins and 
immunodominant peptides. Used as adjuvant, CpG motifs surpassed 
the gold standard of complete Freunds adjuvant (CFA). 
m] Humoral and cellular factors involved in sepsis 
J. Cohen. Hammenmith Hospital, Infections Diseases, London, UK 
The acute-phase response (APK) is an acute physiologic reaction to 
injuries of various kinds, including infections. It consists of well- 
described quantitative and qualitative changes in the synthesis of a 
variety ofhepatic proteins, and is highly conserved in all endothermic 
species, suggesting that it confers a significant survival advantage. 
Detailed studies of acute-phase serum show that it contains a 
multitude of proteinc, including increased levels of complement, 
coagulation and transport proteins, as well as classic acute-phase 
pentraxin proteins, human C-reactive protein and mouse serum 
amyloid component P (SAP). Leukocyte and endothelial cell 
supernatants were found to be potent stimulators of the APR, and 
the pro-inflammatory cytokines TNF-alpha, IL-1 and IL-6 were 
shown to be the active components in the supernatants responsible 
for initiating the APR. Novel observations from our laboratory have 
revealed that the APR appears to have a role in host defense against 
bacterial infection, and data will be presented demonstrating the 
possible mechanisms by which this occurs. The APR is an enor- 
mously complicated physiologic reaction to injury; nevertheless, if it 
can be manipulated it may be of great clinical benefit. 
wl Sensitization of the host to sepsis and septic 
shock 
T. Calandra. CHUY Lausanne, Switzerland 
Upon stimulation with microbial agents such as the endotoxin of 
Gram-negative bacteria, or the exotoxins or cell wall fragments of 
Gram-positive bacteria, monocytes/macrophages, T-cells, neutrophils 
and endothelial cells release mediators that play a critical role in the 
host response to invasion by these microorganisms. Among the 
cytokines released during the acute phase of infection, WNy and 
macrophage migration inhibitory factor (MIF), one of the first 
cytokines discovered, can sensitize the host and augment the inflam- 
matory response. WNy primes resting monocytes and macrophages, 
upregulating HLA-DK expression and LPS-induced cytokine pro- 
duction. WNy has thus been used to reverse nionocyte deactivation 
in critically ill patents. Preliminary results indicate that WNy therapy 
may ameliorate immune dysfunction in these patients (Nature Med 
1997; 3: 678), yet prospective, randomized, double-blind trials are 
needed to determine the efficacy and safety of such adjunctive 
therapy. Recent observations have ascribed a critical role to MIF in 
the host response to infection. MIF was first rediscovered as a pitui- 
tary peptide released in a hormone-like fashion during endotoxemia 
and the physiologic stress response (Nature 1993; 365: 756). MIF was 
then found to also he a macrophage cytokine secreted after pro- 
inflammatory stimuli (LPS, TSST-1, SPEA, TNF-alpha, IFN- 
gamma) 0 Exp Med 1994;179:1895). Like TNF-alpha and IL-1-beta, 
MIF plays an important role in host response to septic shock. Co- 
injection of rMIF and LPS or E .  coli exacerbates lethality, while 
neutralizing anti-MIF antibodies fully protect mice from lethal shock. 
Once released, MIF also functions to counterbalance the anti- 
inflammatory and immunosuppressive effects of glucocorticoids on 
immune cells (Nature 1995; 377: 68). These data implicate IFN- 
gamma and MIF as important mediators of hosr responses to 
infection, that act in concert with glucocorticoids to regulate 
inflammation and innate immune responses to microbial products. 
1x1 Anti-CD14 monoclonal antibody intervention 
protects from LPS-induced organ injury and 
death in a rabbit model of Gram-negative 
septic shock 
J. Mathison. The Research Institute ofeScripps Clinic, Lajollo, CA, 
USA 
During infection, the innate immune system enables immediate 
recognition and clearance of microorganisms and initiation of the 
adaptive iminune response. Unfortunately, the host response to 
microbial components such as Gram-negative endotoxin also leads to 
organ injury, shock and death. CD14, a macrophage membrane 
protein which is also present as a soluble form in plasma, serves as a 
receptor for LPS, suggesting that blockade of CD14 might limit 
inflammatory injury during Gram-negative infection. We developed 
a monoclonal antibody to rabbit CD14 that blocked LPS binding and 
TNF release in peritoneal niacrophages, and we evaluated the efficacy 
ofthis antibody to block LPS-induced injury in a rabbit model where 
pathophysiologic changes induced by multiple injections of LPS were 
observed over 48 h. Pretreatment with anti-CD14 blocked LPS- 
induced cytokine release, neutropenia, hypotension, organ injury and 
death. Importantly, administration of anti-CD14 after the first 
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injections of LPS (and after the initial cytokine release) also prevented 
organ injury and death. In contrast, intervention with anti-TNF 
antibody did not provide significant protection. These results support 
the concept that blocking CDl4 in human septic shock may limit 
hypotension, disseminated intravascular coagulation and organ injury 
reculting from cuniulative exposures to LPS. 
Immune reconstitution in HIV disease 
ml Antiviral therapy of HIV infection 
I.V.D. Weller. Royal  Free and Uiiversiry College Medical Sihool, 
Lhitwsity Collqe Londow, London, UK 
In developed countries, potent combination therapy has led to 
important reductions in morbidity, mortality and hospitalization. 
However, at the same time, as always, we face new challenges. To 
what extent these effects will be sustained is not known. Resources 
and outpatient facilities are being ‘stretched. Poor compliance with 
complicated drug treatments requires a simplification of regimens. 
There is evidence of low-level replication continuing in the face of 
an apparent ‘suppression’ of replication, and together with sanctuary 
sites of virus division, the emergence of resistance in the longer term 
seems inevitable. Resistance may cross drug classes, reducing 
therapeutic options for change. Immune reconstitution is largely 
partial, heightening interest in supplementary immune-based thera- 
pies. Resistance testing is ‘leaking’ into clinical practice before we 
really know how urefuI it is, and when to  start therapy, when to 
change, what to use and how best to sequence drugs are vital 
questions that we need to address. 
wl Maintenance and prophylactic treatment of 
opportunistic infections during HAART 
M.A. Jacobson. Lhitwsi ty  .f Cnl$rnia, San Fraricisco, C4,  [ JSA4 
HAART has profoundly affected the incidence of common AIDS- 
related opportunistic infections (01s) in countries where this therapy 
is widely available. In the USA and western Europe, the incidence of 
C X  such as Pnruniocystis carinii pneumonia (PCP), disseminated 
Alyn)/iaiteriuw~ uvinm complex infection (MAC) and cytoniegalovirus 
end-organ disease (CMV) is now 20% of that in 1994. However, the 
incidence does not appear to have decreased further since 1997. 
There have been several recent reports of individual AIDS patients 
with MAC and CMV on  maintenance therapy for these 01s who, 
after their CD4 count rose to 100 cells/(L on HAART, have discon- 
tinued maintenance therapy without 01 relapse after up to 1 year of 
follow-up. There are also reports of small series of patients who were 
receiving PCP or MAC prophylaxis for CD4 counts <?OO or  50 and 
who, aher their CD4 count row to 200 or  lO(1 ceUs/(L on  HAART, 
have discontinued prophylaxis without developing these 0 1 s .  
However, it is not possible to accurately predict which patients with 
prior low CD4 counts who have responded to HAART can safely 
discontinue 01 maintenance or  prophylaxis treatment. Observational 
studies are in progress to better define markers of01 protection. These 
include pathogen-specific immune function and T-cell phenotype 
assays in addition to standard CD4 and I-UV R N A  measurements. 
Pending results of these trials, continued maintenance and pro- 
phylaxis should be based on nadir CD4 counts unless the risk of anti- 
0 1  drug adverse effects is substantial. 
Thinking like bacteria-the modern 
approach to overcome resistance in Gram- 
negative bacteria 
I S61 I Evolution of resistance mechanisms- 
intelligent bacterial solutions to combat 
antibiotic attack 
P. Heisig. Pilamiaceuticai AliiroDiolo~y, L’nirwsify cf Borm, Germany 
It is generally assumed that a pool of resittance genes evolved in 
antibiotic-producing microorganisms before antibiotics were u\ed fix 
treatment of infectious diseases. These genes code for antibiotic.- 
inactivating enzymes, like beta-lactamases, as well as target-modif+g 
enzymes like rRNA niethylases. Moreover, efflux pumps reducing 
the intracellular drug concentration have evolved with narrow o r  
broad substrate specificities. The  spread of the corresponding re\i\t- 
ance genes among different bacteria seems to have been primarily 
influenced by the local selective pressure within the natural environ- 
ment. However, during the last decade, conditions of selection have 
changed rapidly due to the intensive use of antibiotics and the 
development of new drugs. But within a short period of time, 
bacteria have developed effective defense mechanisms against every 
new drug introduced. Besides the transfer of preformed reristance 
determinants, point mutations have played a major role in this short- 
term resistance development. These point mutations have affected 
not only genes coding for already existing inactivating enzymes (a‘ i~4 ,  
tila) or regulatory elements controlling efflux pumps (nwz4, mcx), but 
also genes coding for targets of antibiotic action. These include genes 
like rpoB, coding for the target of rifampin, or  genes yyr’4 m d  ynrC,  
coding for the A subunits oftype I1 topoisomerases, DNA gyrase and 
topoisomerase IV, respectively These are the tax-gets inhibited by the 
synthetic quinolones. Due to the high antibacterial activity of new 
fluorinated quinolones against E.  coli, a combination of mutationr is 
required for clinically relevant levels of resirtance. Observations with 
laboratory strains suggest that the accumulation of rerittance muta- 
tions siinultaneously reduces the viability. Thus, additional mutations, 
not necessarily affecting resistance, are aqsumed to restore fitness, a5 
has been observed in fluoroquinolone-resistant clinical isolates. 
Quorum sensing: the language of 
Gram-negative bacteria 
G. Hartman, Greenwich Hcaltlicare Nh’S  Tkv,  Dcp. of Medical 
hlicrohiology, London, UK 
The  discovery of N-acyl-L-homoserine lactone molecules as the 
signaling mechanism in Pliofobmrriuni ( I  ‘ibuio) j s c h e r i  to \en\e m d  
respond to their own density in the light organr of certain fish in 
order to bring about the quorum rerponre of bioluminescence has 
led to the elucidation of similar mechanisms in an ever-increasing 
number of Gram-negative organisms-to the extent that quorum 
sensing appears to be a universal lanpage of Grani-negative bacteria. 
In at least one human pathogen, Psc~~domi~inas erqinosa, quorum 
sensing appears to control the expresion of numerous virulence 
factors such as elastase, exotoxin A, pyocyanin, alkaline proteate, 
cyanide and hemolytin. Interestingly, there even appears to be the 
capability of interspecies communication, with Burkholdcrio ctpacio 
being able to sense and respond to the density of Pseudomunus 
aerqinosa in the lungs of cystic fibrotic patients. Uvng a model bascd 
on the luminescence operon of Photobaiferinm js iheri ,  several poten- 
tial mechanisms to disrupt quorum sensing, and, hence. patho- 
genicity, may be possible. Currently, the most attractive of these i\  t o  
use compounds resembling the n’-acyl-L-honioseriiie lactone 
